Our study, which is the first genetic study of its kind in Brunei, showed that the overall combined frequency of germline pathogenic BRCA1 and BRCA2 mutation carriers among 120 recruited Brunei’s breast cancer patients was 5% (n = 6), which is lower than those reported at 12.3% in women of European descendent [52]. The gene discussed is BRCA2; the disease is breast carcinoma.